Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

LEVOTHYROXINE (SODIUM)

All products: general benefit

Other products in the same Health Canada class (H03AA) — coverage varies; not interchangeable

  • Liothyronine (Cytomel): not a benefit

Synthroid · DIN 02172127 · 0.15mg · tablet

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Synthroid · DIN 02172127 Manufacturer: Abbott Laboratories Limited; listing date 1996-10-01 Health Canada: Marketed since 2016-03-10 · brand SYNTHROID · ATC H03AA01 LEVOTHYROXINE SODIUM · form Tablet · route Oral · ingredients LEVOTHYROXINE SODIUM 150 MCG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.0495 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19598 · Verify on the e-Formulary ↗ (DIN 02172127)

Source record
DIN 02172127: Synthroid Raw flags: sec3=Y Item: 683600011; group id 805; item number 1977; lccId None; manufacturer id ABB Source form: Tab; strength: 0.15mg Recorded listing: General benefit Source prices (unrounded): $0.1051; ministry $0.0495 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02172127 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19598
Interchangeable products
Apo-Levothyroxine · DIN 02550784 · $0.0495 Eltroxin · DIN 02213214 · $0.0495
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:36 Thyroids) and how they are covered

Matched class: 68:36 Thyroids

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: PROPYLTHIOURACIL 68:36 Thyroids

LIOTHYRONINE (SODIUM)

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mcg, 25mcg · Tab

PROPYLTHIOURACIL

· 2 products · General benefit · strengths: 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:36
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS SYNTHROID® (levothyroxine sodium) is indicated for: Hypothyroidism SYNTHROID® is indicated as a replacement or supplemental therapy in patients of any age with primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism of any etiology, in any state (including pregnancy) except transient hypothyroidism during the recovery phase of subacute thyroiditis; Pituitary Thyrotropin (Thyroid-stimulating hormone, TSH) Suppression SYNTHROID® is indicated as an adjunct to surgery and radioactive iodine therapy in the management of thyrotropin-dependent well-differentiated papillary or follicular carcinoma of the thyroid. 1.1 Pediatrics Pediatrics (<18 years of age including neonates): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of SYNTHROID® in pediatric patients has been established. Therefore, Health Canada has authorized an indication for pediatric use (see 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment, Pediatric Dosage). 1.2 Geriatrics Geriatrics (≥65 years of age): SYNTHROID® is approved for use in the geriatric population. However, experience suggests that use in the ge… https://pdf.hres.ca/dpd_pm/00077309.PDF PM date: OCT 08, 2024 Source product: SYNTHROID; DIN 02171228; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.